Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies, University of Melbourne Partner on Breast Cancer Risk Test

NEW YORK (GenomeWeb) – Australian molecular diagnostics firm Genetic Technologies announced today that it has partnered with the University of Melbourne to broaden the applicability of its BrevaGenplus breast cancer risk assessment test.

Genetic Technologies' BrevaGenplus is currently designed for women aged 35 years or older who have not had breast cancer but who have one or more risk factors. In collaboration with the University of Melbourne, the company is aiming to expand the test's use to women with an extended family history of the disease, and increase the range of risk factors analyzed by the test.

Additional terms of the deal were not disclosed.

In addition to BrevaGenplus, Genetic Technologies is developing a colorectal cancer risk assessment test. The company also recently partnered with Omix Ventures to develop and access a blockchain-based global genomic data management platform for cancer diagnostic development.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more